세계 제산제 시장 규모는 2024년 72억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 97억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 3.4%를 보일 것으로 전망하고 있습니다. 시장 성장의 주요 원인은 소매 약국 확대, OTC 의약품에 대한 선호도, 위식도 역류질환(GERD) 환자 수 증가가 시장 성장을 견인하고 있기 때문입니다.
주요 시장 성장 촉진요인 : 제산제 수요를 자극하는 것은 GERD로 고통받는 사람들이 전 세계적으로 증가하고 있다는 것입니다. 이는 시장 성장을 가속하는 중요한 요인 중 하나입니다.
주요 시장 동향 : 수박민트, 과일 시리얼, 딸기 밀크쉐이크 등 주요 업체들이 맛을 낸 츄어블 유형의 제산제를 출시하면서 제산제 시장 수익에 긍정적인 영향을 미치고 있습니다.
지리적 동향 : 아시아태평양은 제산제의 가장 규모가 큰 지역 시장입니다. 이는 의료비 지출 증가, 고령화, 의료 부문의 확대에 기인합니다.
과제와 기회: 제산제 시장의 도전은 위산 역류에 대한 대체 치료제의 존재이며, 기회는 신흥 시장과 소화기 질환을 치료하는 혁신적인 제형에 있습니다.
위식도역류질환(GERD)의 영향
고령인구 증가에 따른 인구통계학적 변화
노인들은 신맛에서 빠르게 해방되는 제산제의 중요성을 잘 알고 있습니다. 그 결과, 이러한 소화기 질환을 관리하기 위해 제산제를 정기적으로 복용하는 소비자와 구매자가 증가하고 있습니다. 2022년 세계보건기구(WHO)의 보고서에 따르면 2030년, 2030년, 2050년에는 6명 중 1명이 60세 이상이 될 것으로 예상되며, 60세 이상 세계 인구도 2020년 14억 명에서 21억 명으로 증가할 것으로 예측됩니다.
접근성 때문에 일반의약품(OTC)에 대한 의존도 증가
처방전 없이 구입할 수 있는 치료제는 가벼운 증상을 치료하기 위해 전 세계적으로 매우 선호되고 있으며, 이는 제산제에 대한 수요를 불러일으키고 있습니다. 제산제는 약국, 식료품점, 온라인 플랫폼에서 쉽게 구할 수 있으며, 그 결과 자가 치료 목적으로 중요한 역할을 하고 있습니다. IMARC Group의 조사 보고서에 따르면, 2032년까지 일반의약품(OTC) 세계 시장 규모는 2,759억 달러에 달할 것으로 예측됩니다.
The global antacids market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033. The market is experiencing growth mainly because of the expansion of retail pharmacies, preference for OTC drugs, and rising number of patients experiencing gastroesophageal reflux disease (GERD) are impelling the growth of the market.
Major Market Drivers: People suffering from GERD is increasing around the world, which is catalyzing the demand for antacids. This represents one of the key factors propelling the market growth.
Key Market Trends: The launch of flavored and chewable antacids drugs by key players like watermelon mint, fruity cereals, and strawberry milkshake is positively impacting the antacids market revenue.
Geographical Trends: Asia Pacific is the largest regional market for antacids because of the rising healthcare expenditure, aging population, and healthcare sector expansion.
Key Players: Some of the major market players in the antacids industry include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., among many others.
Challenges and Opportunities: Challenges in the antacids market are the presence of alternative treatment for acid reflux, while opportunities lie in emerging markets and innovative formulations to treat digestive issues.
Gastroesophageal reflux disease's (GERD) impact
Changing demographics because of rising geriatric population
Elderly people are understanding the importance of antacids because of their quick relief qualities from acidity. They are, as a result, a regular consumer or buyer of antacids to manage these digestive issues. It may be said that nations with increased aging population rates can have higher sales of antacids worldwide. As claimed by the World Health Organization's (WHO) report of 2022, 1 individual out of 6 will be of 60 years in age or over by 2030 and by 2050. The global population of those aged 60 and over will also reach 2.1 billion, up from 1.4 billion in 2020.
Rising reliance on over the counter (OTC) medicines due to their ease of availability
Non-prescribed remedies are highly preferred in the world to cure mild symptoms, which is catalyzing the antacids demand. Antacids are easily available via pharmacies, grocery stores, and online platforms and as a result play a crucial role in self-medication purposes. The cost-effectiveness and time saving benefits provided by antacids are making them highly suitable for people nowadays. The IMARC Group's research report mentions that the global market for over the counter (OTC) drugs will reach US$ 275.9 Billion by 2032.
Proton pump inhibitors accounts for the majority of the market share
Proton pump inhibitors are so effective and reliable that everyone wants them to cut down on stomach acid and indigestion. Healthcare professionals prescribed them as per the severity of acid reflux, leading to their higher sales. Key players are expanding their market as they know people are gaining knowledge about the positive impact of proton pump inhibitors in the body. For instance, Daewon Pharmaceutical introduced its first proton pump inhibitor medicine in Korea in 2022, known as Escorten.
Tablet holds the largest share of the industry
Easy storage, transportation, and administration are some benefits provided by tablets make them highly preferable among individuals. Tablets are hassle-free, as they can be easily consumed with water anywhere or on the go. Whether at office, home, or travel, people can get quick relief from acidity or indigestion through tablet drugs. The extended shelf life of tablets is viewed as another benefit compared to liquid or powder formulation type. Various tablets formulations present in the antacids market like chewable, delayed release, and effervescent are further creating a strong consumer base.
Retail pharmacies represent the leading market segment
In the first place, cities, suburbs, and rural areas all have numerous retail pharmacies around the world. Antacids as OTC drugs are highly popular & retail pharmacies are a significant outlet to purchase antacids. Secondly, the inclusion of a wide variety of antacids drugs in retail pharmacies can cater to several patients according to their preferences and demands. Thirdly, the focus of leading competitors in the retail pharmacy market on acquisition & expansion to increase their reach. The acquisition of Pharmaca by Medly Pharmacy in 2021 to deliver 360-degrees pharmacy services is one such example.
Asia Pacific leads the market, accounting for the largest antacids market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific enjoys the leading position in the market.
The densely populated countries like India and China are the largest markets for antacids in this region, as these countries are undergoing lifestyle shifts and Western food habits, which generally results in acid reflux and indigestion. Moreover, aging population in the region is viewed as an antacids market recent opportunities due to their high susceptibility to digestive issues. In line with this, lots of key players are present in the Asia Pacific region that are highly competitive and focus on partnerships and acquisition to expand their market. This was done by Dr. Reddy's Laboratories, a pharma company in India, when it acquired MenoLabs from Amyris Inc. in 2024 to cater to the evolving needs of people in the Asia Pacific region.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major antacids companies have also been provided. Some of the major market players in the antacids industry include:
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
The development of new formulations and product variants is done by key players through research and development (R&D) activities. They are introducing antacid drugs with flavors such as Fruity Cereal to meet the evolving demands of consumers. Top companies are taking advantage of elevated awareness about gastrointestinal health among people in developing countries. They are also eyeing on acquiring small businesses in the market while creating opportunities via antacids market recent developments. Using the digital health solutions is the main help method, enabling them to provide better health results. One such example was presented by AstraZeneca in November 2023, which it launched Evinova, a health-tech business, to offer advanced digital health solutions.